Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects With Type 2 Diabetes.

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects With Type 2 Diabetes.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Albiglutide (Primary) ; Metformin; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms HARMONY 1; HARMONY-1
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 10 Jun 2021 According to a Harmony Biopharm media release, data from this trial was presented at the 35th Annual Meeting of the Associated Professional Sleep Societies (APSS).
  • 10 Jun 2021 Results published in Harmony Biosciences Media Release
  • 14 Oct 2020 According to a Harmony Biosciences media release, U.S. Food and Drug Administration (FDA) has approved WAKIX(pitolisant) for the treatment of cataplexy in adult patients with narcolepsy.FDA approval of WAKIX for the treatment of cataplexy in adult patients with narcolepsy is based on the results from HARMONY CTP and HARMONY 1 from the clinical development program for WAKIX.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top